furmonertinib + pemetrexed + carboplatin + bevacizumab

This is a combination regimen consisting of four drugs: **Furmonertinib** is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively targets both EGFR-sensitizing and T790M resistance mutations, primarily used in the treatment of non-small cell lung cancer (NSCLC). **Pemetrexed** is an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, leading to inhibition of DNA and RNA synthesis. **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. This combination regimen has been investigated as first-line or subsequent therapy for advanced or metastatic non-squamous NSCLC, particularly in patients with EGFR mutations or after progression on prior EGFR TKI therapy[1][6][7]. The rationale for this combination includes targeting tumor proliferation via multiple mechanisms—EGFR inhibition, cytotoxic chemotherapy, and antiangiogenic blockade.

Brand names

Alflutinib (for furmonertinib, in China)Alimta (for pemetrexed)Avastin (for bevacizumab)